Vitrolife AB Interim report Q3, 2024: Improved growth with solid margins
Vitrolife reported strong Q3 2024 performance with sales reaching SEK 867 million, showing a 7% increase in local currencies.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vitrolife reported strong Q3 2024 performance with sales reaching SEK 867 million, showing a 7% increase in local currencies. The company saw regional growth of 9% in EMEA, 2% in Americas, and 9% in APAC. Business areas showed varied performance with Consumables up 13%, Technologies up 11%, while Genetics remained flat. The gross margin improved to 58.6% from 55.7%. EBITDA reached SEK 289 million with a 33.4% margin. For the first nine months, total sales were SEK 2,650 million, with a 4% increase in local currencies and improved EBITDA of SEK 888 million.
Positive
- Sales increased 7% in local currencies to SEK 867 million in Q3
- Gross margin improved to 58.6% from 55.7% in Q3
- Strong regional growth in EMEA and APAC (both +9%)
- Consumables and Technologies segments showed double-digit growth (13% and 11%)
- Nine-month EBITDA increased to SEK 888 million with improved margin of 33.5%
- Earnings per share for nine months improved to SEK 2.76 from SEK 2.42
Negative
- Operating cash flow decreased to SEK 206 million from SEK 214 million in Q3
- Q3 net income declined to SEK 116 million from SEK 122 million
- Genetics business segment showed 0% growth in Q3
- Americas region showed weak growth of only 2% in Q3
Details
News Market Reaction – VTRLY
The recorded move for VTRLY in the trading session of this news was -23.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GOTHENBURG, Sweden, Oct. 24, 2024 /PRNewswire/ --
Third quarter
- Sales of SEK 867 (848) million, an increase of
7% in local currencies and2% in SEK.
- Sales per region, in local currencies was +
9% in EMEA, +2% in Americas and +9% in APAC.
- Sales per business area, in local currencies was +
13% in Consumables, +11% in Technologies and0% in Genetics.
- Gross margin increased to
58.6% (55.7).
- Operating income before depreciation and amortisation (EBITDA) was SEK 289 (287) million, giving an EBITDA margin of
33.4% (33.9).
- Operating cash flow decreased to SEK 206 million (214).
- Net income was SEK 116 (122) million, resulting in earnings per share of SEK 0.85 (0.90).
First nine months
- Sales of SEK 2,650 (2,607) million, an increase of
4% in local currencies and2% in SEK.
- Sales per region, in local currencies was +
6% in EMEA, -2% in Americas and +7% in APAC.
- Sales per business area, in local currencies was +
10% in Consumables, +20% in Technologies and -7% in Genetics.
- Gross margin increased to
58.6% (56.1).
- Operating income before depreciation and amortisation (EBITDA) increased to SEK 888 (842) million, giving an EBITDA margin of
33.5% (32.3).
- Operating cash flow increased to SEK 640 million (586).
- Net income was SEK 375 (328) million, resulting in earnings per share of SEK 2.76 (2.42).
Gothenburg, October 24, 2024
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO
The information was submitted for publication, through the agency of the contact persons set out above, at 24-10-2024 08:00 CET.
Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Interim report Q3, 2024 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.